Navigation Links
Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
Date:4/13/2009

via(TM) in Asia.

About Raptor Pharmaceuticals Corp.

Raptor Pharmaceuticals Corp. ("Raptor") is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. Raptor focuses on underserved patient populations where it believes it can have the greatest potential impact. Raptor currently has product candidates in clinical development to treat nephropathic cystinosis, non-alcoholic steatohepatitis ("NASH"), Huntington's Disease ("Huntington's"), and aldehyde dehydrogenase ("ALDH2") deficiency.

Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins that are designed to target cancer, neurodegenerative disorders and infectious diseases.

For additional information, please visit www.raptorpharma.com.

FORWARD LOOKING STATEMENTS

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limited to the following statements: that Dr. Rioux' successful clinical and regulatory track record will benefit and / or advance the Company's clinical-stage programs through the clinic and into the market; that the Company's pipeline could address serious unmet medical needs; that the Company will be successful in initiating and / or completing its planned clinical trials; that the Company will successfully file an NDA in 2010; that clinical results from planned or ongoing clinical trials will be available as planned or that th
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
2. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
3. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
4. Raptor Pharmaceuticals Provides Update on Targeting Platforms
5. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
6. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
7. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
8. Raptor Pharmaceuticals Provides Update of Product Programs
9. Strativa Pharmaceuticals Provides Product Pipeline Update
10. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
11. Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014  RESMED INC. (NYSE: RMD ) ... fiscal year ended June 30, 2014 results on Thursday, July ... A press release with ResMed,s results will be issued after ... a webcast to discuss operating results and future outlook. ... p.m. US Pacific Time and the live webcast of the ...
(Date:7/10/2014)... , July 10, 2014  Decision Resources ... surveyed infectious disease (ID) specialists are willing to ... Orbactiv (oritavancin) for use as OPAT, approximately two-thirds ... these agents to their hospital inpatients. However, our ... OPAT patients are initiated on OPAT following hospital ...
(Date:1/15/2014)... -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry Report, 2013-2015" ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting from aging ... China,s orthopedic instrument industry has seen rapid ... from 3.28 billion yuan in 2006 to 9.85 billion ...
Breaking Medicine Technology:ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3
... DecisionView Inc., a leading provider of software ... sciences companies, today announced the release of StudyOptimizer ... solution for patient enrollment planning, tracking and forecasting. ... site performance and cost projections, StudyOptimizer 4.3 significantly ...
... Mich., July 19, 2011 Terumo Heart, Inc., a ... a patient implanted with the DuraHeart™ Left Ventricular Assist ... the mechanical circulatory support device.  Helga Gieseke, living in ... German Heart Institute Berlin) and is now one of ...
Cached Medicine Technology:DecisionView StudyOptimizer 4.3™ Enhances Market-Leading Enrollment Optimization Solution With Greater Visibility Into Site Performance and Cost Forecasting 2DecisionView StudyOptimizer 4.3™ Enhances Market-Leading Enrollment Optimization Solution With Greater Visibility Into Site Performance and Cost Forecasting 3German Patient Surpasses 5 Years of Support on DuraHeart™ Left Ventricular Assist Device 2German Patient Surpasses 5 Years of Support on DuraHeart™ Left Ventricular Assist Device 3
(Date:7/13/2014)... Athletes with a certain genetic make-up are ... to research presented today at the American Orthopaedic Society ... research marks the first of its kind investigating a ... events that occur after a head injury. , ... the (GT)n genotype were four times more likely to ...
(Date:7/13/2014)... Recently, 2014QuinceaneraDresses.com, the distinguished special occasion dress manufacturer ... gorgeous Quinceanera dresses . , In ... outfits is huge. Therefore, 2014QuinceaneraDresses.com is striving to ... released dresses are made according to the latest ... , It is worthy of mention that ...
(Date:7/13/2014)... Recently, MyDressCity.com, one of the most popular suppliers ... released its new range of elegant Quinceanera dresses ... at discounted prices. Worldwide clients can enjoy this special ... company’s online shop, there are plenty of beautiful dresses ... great materials. MyDressCity.com’s hot items are prom gowns, bridesmaid ...
(Date:7/13/2014)... 13, 2014 Epidemiologists forecast an increase ... 6MM, from 8,062 diagnosed incident cases in 2013 to ... Growth Rate (AGR) of 4.35%, during the forecast period. ... of diagnosed incident cases of aGVHD in the 6MM, ... the lowest number of diagnosed incident cases of aGVHD, ...
(Date:7/13/2014)... 13, 2014 A decreased ability to identify ... and Alzheimer,s disease, while examinations of the eye ... associated with Alzheimer,s, in the brain, according to ... at the Alzheimer,s Association International Conference 2014 (AAIC ... studies, the decreased ability to identify odors was ...
Breaking Medicine News(10 mins):Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7
... Rajasthan High Court issued notice to the state government ... silicosis. ,The public interest litigation (PIL), filed ... pleaded that the labor force needed to be protected ... of the state government and the malpractice of the ...
... $100,000 of their money to help// construct the first modern ... the donation to the Duk Lost Boys Clinic through the ... spring and serve more than 150,000 people. ... "lost boys" of Sudan who is the director of non-profit ...
... governments to join the anti-tuberculosis global plan, which would ... disease has become extremely drug-resistant. ,Ban's message ... on Saturday. The World Health Organization (WHO) recently reported ... of tuberculosis, XDR-TB, which threatens to derail efforts to ...
... An alarming 20 percent of the people availing re-treatment of ... India. According to a leading global health advocacy, India witness ... the eve of the World TB Day, March 24, the ... TB drug resistance is becoming a major threat for several ...
... harmful for pregnant women and may cause degeneration of their ... ,The musculoskeletal system gives human beings and animals the ability ... The cardiovascular system is composed of the heart, blood vessels, ... the blood. ,Doctors often advice women to ...
... Court about its plan to technologically upgrade its forensic ... up all its vacancies to facilitate quick investigation into ... appearing before a bench of Justice T.S. Thakur and ... steps to fill up about 45 vacancies in the ...
Cached Medicine News:Health News:Public Interest Litigation Filed Favoring Mineworkers Against Silicosis 2Health News:Tuberculosis Drug Resistance 'alarming' in India 2Health News:Rohini Forensic Lab to Be Upgraded 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: